Merck Drug Extends Survival in Endometrial Cancer Trial
Merck said its drug extended survival in a trial involving endometrial cancer.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
3 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
Merck Drug Extends Survival in Endometrial Cancer Trial, Gets US Priority Review
Merck’s drug extended survival in an endometrial cancer trial and received priority review in the United States.
Merck Experimental Therapy Extends Survival in Advanced Endometrial Cancer Trial
Late-stage trial data presented at the ESMO medical congress showed Merck’s experimental targeted drug helped women with advanced endometrial cancer live longer and kept their disease in check versus standard treatment.